@article {El-Haddadjnmt.121.262423, author = {Ghassan El-Haddad and Remy Lim and Jessica Fegan and Rudresh Chandrashekar}, title = {Stability matters: Radiochemical stability of therapeutic radiopharmaceutical of 177Lu-PSMA-I\&T}, elocation-id = {jnmt.121.262423}, year = {2022}, doi = {10.2967/jnmt.121.262423}, publisher = {Society of Nuclear Medicine}, abstract = {Labelling radiopharmaceuticals and testing the quality of the labelled product before injecting it into patients are standard operating procedures in the Nuclear Medicine department. There is a different shelf life for each labelled product, which determines how long a product can maintain in-vitro stability before it needs to be discarded. Lutetium-177 (177Lu) is a radioactive isotope that is increasingly being accepted into the treatment paradigm for palliation of advanced-stage tumours, including metastatic castration-resistant prostate cancer (mCRPC) and neuroendocrine tumours (NET). In our institution, synthesis of 177Lu with prostate-specific membrane antigen imaging and therapy (PSMA-I \& T) for palliation of mCRPC is performed on Eckert \& Ziegler Eurotope{\textquoteright}s Modular-Lab Pharm Tracer{\textregistered} automated synthesis system. Sterile GMP-certified no-carrier-added 177Lu is supplied by Australia{\textquoteright}s Nuclear Science and Technology Organization (ANSTO). Following each synthesis, the final product quality is evaluated by High-performance liquid chromatography (HPLC) and instant thin-layer chromatography (ITLC) at three different time points: 0 hours, 24 hours, and 48 hours. Between February 2020 to October 2020, the quality of 35 batches of 177Lu-PSMA-I \& T was evaluated. The average radiochemical purity of ITLC-SG was found to be greater than 99 percent (99.70{\textpm}05\%), and HPLC was greater than 98 percent (98.60{\textpm}0.05\%). Our findings demonstrate that automated synthesis of 177Lu-PSMA-I \& T with Eckert \& Ziegler Eurotope{\textquoteright}s Modular-Lab Pharm Tracer{\textregistered} can remain stable for 48 hours post labelling.}, issn = {0091-4916}, URL = {https://tech.snmjournals.org/content/early/2022/06/14/jnmt.121.262423}, eprint = {https://tech.snmjournals.org/content/early/2022/06/14/jnmt.121.262423.full.pdf}, journal = {Journal of Nuclear Medicine Technology} }